PATIENT OR CAREGIVER
Home  |  Privacy Policy  |  Terms and Conditions  |  Contact Medical Information  |  Site Map

Hemodynamic Data in Pulmonary Hypertension Associated with Scleroderma Spectrum of Diseases (PAH/SSD)

Significant Improvement in Hemodynamics1

In a 12-week, prospective, open-label, randomized trial, statistically significant differences in cardiac index, mean pulmonary arterial pressure, and pulmonary vascular resistance were observed in patients who received epoprostenol plus conventional therapy compared with those who received conventional therapy alone. These hemodynamic parameters generally worsened in the group receiving conventional therapy alone. Except for 5 NYHA Functional Class II patients, all patients were either Functional Class III or IV. Conventional therapy could include anticoagulants, oral vasodilators, supplemental oxygen, digoxin, and/or diuretics.1

* Denotes statistically significant difference between epoprostenol and conventional therapy groups (n is the number of patients with hemodynamic data).1

CI: cardiac index; mPAP: mean pulmonary arterial pressure; mRAP: mean right atrial pressure; PVR: pulmonary vascular resistance; mSAP: mean systemic arterial pressure.